LQDA Liquidia Corporation

56.63USD+0.41%Mkt Cap: 5.10B USDP/E: —

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPI…

Insiders, last 90 daysNet sellers
Institutional holders20 on file

Key Statistics

Company
Market Cap5.10B USD
Enterprise Value4.85B USD
Revenue (TTM)621.87M USD
Gross Profit145.08M USD
Net Income (TTM)-68.92M USD
Revenue/Share7.04 USD
Last Price56.63 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees216
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)15.73
PEG—
EV/EBITDA16.50
EV/Revenue7.81
P/S8.21
P/B-200.11
EPS (TTM)-1.06 USD
EPS (Forward)3.44 USD
52W Range
22.3148% of range93.61
52W High93.61 USD
52W Low22.31 USD
Profitability
Gross Margin91.64%
Oper. Margin47.12%
EBITDA Margin47.31%
Profit Margin-43.53%
ROE-154.03%
ROA-21.02%
ROIC-78.06%
ROCE-26.74%
Growth
Revenue Growth314.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-35.69M USD
CapEx (TTM)6.34M USD
FCF Margin86.13%
FCF Yield10.50%
Net Debt-227.33M USD
Net Debt/EBITDA-0.77
Net Debt/FCF-0.42
Balance Sheet
Debt/Equity4.42
Current Ratio1.02
Quick Ratio0.86
Book Value/Sh-0.28 USD
Cash/Share4.40 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.6 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)66.13 USD
Upside (mean)+16.8%
Target Range40.00 USD – 87.00 USD
40.00+16.8% to mean87.00
# Analysts8
Ownership
Shares Out.90.11M
Float65.81M
Insiders9.15%
Institutions85.09%
Short Interest
Short Ratio2.5d
Short % Float24.07%
Short % Out.19.43%
Shares Short17.51M
Short (prev mo.)12.64M
Technical
SMA 5048.72 (+16.2%)
SMA 20054.78 (+3.4%)
Beta0.41
S&P 52W Chg12.08%
Avg Vol (30d)3.55M
Avg Vol (10d)2.63M
Technical Indicators
RSI (14)64.7
MACD3.4139
MACD Signal2.0412
MACD Hist.+1.3727
BB Upper61.26 USD
BB Middle49.20 USD
BB Lower37.15 USD
BB Width49.00%
ATR (14)3.643 USD
Vol Ratio (20d)0.51x

About Liquidia (NASDAQ: LQDA)

›

Liquidia (NASDAQ: LQDA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 216 employees.

The shares were at 56.63 USD on 19 November 2026, up 121.2% over 52 weeks. Its 52-week range is 22.31 USD to 93.61 USD: the price is 39.5% below the high and 153.8% above the low.

Its market capitalisation is 5.10B USD.

Liquidia reports return on equity of -154.0%, an operating margin of 47.1% and revenue up 314.6% year over year.

It holds more cash than debt, a net cash position of 227.33M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 8 analysts cover the stock, with an average rating of Buy; their mean price target of 66.13 USD is 16.8% above the current price. The next earnings report is expected on 11 March 2027.